论文部分内容阅读
目的：研究血小板激活因子拮抗剂ＢＮ５２０２１对大鼠缺血再灌注肝脏的影响。方法：将大鼠分为三组，对照组未进行缺血及药物治疗；缺血再灌注组行４０ｍｉｎ缺血，然后行１２０ｍｉｎ再灌注；血小板激活因子拮抗剂治疗组行４０ｍｉｎ缺血，１２０ｍｉｎ再灌注，再灌注时给予ＢＮ５２０２１（１０ｍｇ／ｋｇ），比较各组血清ＳＧＰＴ、ＳＧＯＴ、ＡＫＰ及γ－ＧＴ，肝脏的细胞能荷。结果：用血小板激活因子拮抗剂治疗组血清ＳＧＰＴ、ＳＧＯＴ、ＡＫＰ、γＧＴ均较缺血再灌注组显著降低，能荷水平明显升高。结论：血小板激活因子拮抗剂ＢＮ５２０２１用于大鼠肝脏缺血再灌注可减少肝脏的损害，提示血小板激活因子（ＰＡＦ）对肝脏缺血再灌注损伤的发生起一定的作用，血小板激活因子拮抗剂ＢＮ５２０２１有可能用于肝脏缺血再灌注损伤的治疗。
Objective: To study the effect of platelet activating factor antagonist BN52021 on the hepatic ischemia reperfusion in rats. Methods: The rats were divided into three groups, the control group was not ischemic and drug treatment; ischemic reperfusion group 40min ischemia, then 120min reperfusion; platelet activating factor antagonist group 40min ischemia, 120min and then BN52021 (10mg / kg) was given during perfusion and reperfusion. The serum SGPT, SGOT, AKP and γ-GT in serum of each group were compared. Results: Serum SGPT, SGOT, AKP, γGT were significantly lower than those of ischemia-reperfusion group and the energy charge level was significantly increased with platelet-activating factor antagonist treatment group. Conclusion: Platelet-activating factor antagonist BN52021 can reduce hepatic ischemia-reperfusion injury in rats, suggesting that platelet activating factor (PAF) may play a role in the pathogenesis of hepatic ischemia-reperfusion injury. Platelet-activating factor antagonist BN52021 It is possible for the treatment of liver ischemia-reperfusion injury.